COMPASS Pathways Plc American Depository Shares (CMPS) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
COMPASS Pathways Plc American Depository Shares (CMPS) has outperformed Syndax Pharmaceuticals (SNDX) over the past year, gaining 87.3% versus a gain of 3.5%. Over five years, SNDX leads with a -8.4% price change compared with -63.7% for CMPS. COMPASS Pathways Plc American Depository Shares is the larger company by market cap ($1.57 billion vs $1.53 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPS | SNDX |
|---|---|---|
| Share price | $11.35 | $17.14 |
| Market cap | $1.57B | $1.53B |
| 1-day change | -2.95% | +0.62% |
| YTD return | +69.42% | -18.94% |
| 1-year return | +87.34% | +3.53% |
| 5-year return | -63.72% | -8.39% |
| EPS (TTM) | $-3.76 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.87 | $25.59 |
| 52-week low | $4.88 | $12.99 |
| Distance from 52-week high | -28.51% | -33.04% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +109.34% | +119.14% |
| Average volume | 3.04M | 1.54M |
| Shares outstanding | 138.48M | 89.30M |
| Employees | 156 | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CMPS has outperformed SNDX by 83.8 percentage points over the past year.
About COMPASS Pathways Plc American Depository Shares
CMPS stock →COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 156 employees
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
CMPS vs SNDX FAQ
Which is bigger, COMPASS Pathways Plc American Depository Shares or Syndax Pharmaceuticals?
COMPASS Pathways Plc American Depository Shares (CMPS) is larger, with a market capitalization of $1.57B compared with $1.53B for Syndax Pharmaceuticals (SNDX).
Which stock has performed better over the past year, CMPS or SNDX?
CMPS returned +87.34% over the past 12 months, compared with +3.53% for SNDX (price return, excluding dividends). Past performance does not predict future results.
Are COMPASS Pathways Plc American Depository Shares and Syndax Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.